|Bid||0.00 x 2900|
|Ask||0.00 x 800|
|Day's Range||6.01 - 6.19|
|52 Week Range||2.73 - 6.45|
|Beta (5Y Monthly)||2.73|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 10, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.00|
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today provided an update on upcoming milestones for its COM701 and COM902 clinical programs and highlighted 2019 accomplishments.
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the appointment of Oliver Froescheis, Ph.D., as Senior Vice President, Corporate and Business Development. In his role, Dr. Froescheis will oversee the Company's business development strategy and execution, reporting to Anat Cohen-Dayag, Ph.D., Compugen's President and CEO. Dr. Froescheis joins Compugen from Roche's Partnering organization where he most recently served as Director of Business Development and Licensing R&D; Out-licensing.
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 26% in 2019 (through November 22nd). Conversely, hedge […]
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: ^NBI). Compugen's addition to the NBI will become effective prior to market open on Monday, December 23, 2019.
Janpix, Inc., a privately-held biopharmaceutical company dedicated to the discovery and development of inhibitors/degraders of Signal Transducer & Activator of Transcription (STAT) proteins for oncological indications, announced today the appointment of Sanford Zweifach as the Company’s Executive Chairman of the Board of Directors. Mr. Zweifach brings to Janpix almost 30 years of experience in senior executive roles in the life sciences industry, with a focus in corporate partnering, business development, operations, private and public investing, and capital raising.
The biotech sector recovers on the back of rising M&A activities and pipeline successes in 2019 after a dismal 2018. Here we discuss five biotech companies recording impressive growth.
The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you...
Preliminary Phase 1 clinical data presented at SITC 2019 demonstrate COM701 is well-tolerated with initial signals of anti-tumor activity Initiation of COM902 Phase 1 study in patients with advanced malignanciesplanned ...
HOLON, Israel, Nov. 6, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that The European Patent Office (EPO) has granted a new patent covering the composition of matter and use of COM902, its immuno-oncology therapeutic antibody targeting TIGIT. EPO Patent No. EP3347379, titled "Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof," relates to the composition of matter of COM902, alone or in combination with a second antibody targeting an immune checkpoint, including PD-1 and PVRIG (specifically COM701). The patent further relates to COM902 for use in treating cancer by activating T cells, a key driver of immune stimulation and cancer immunotherapy treatments.
Data support potential clinical use as a cancer immunotherapy treatment in various combinations with COM701 and PD-1 inhibitors HOLON, ISRAEL , Nov. 5, 2019 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), ...
HOLON, Israel, Nov. 5, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today disclosed preliminary results from its ongoing Phase 1 dose escalation study of COM701, a first-in-class anti-PVRIG antibody, in patients with advanced solid tumors. COM701 was well-tolerated with no dose-limiting toxicities observed. Furthermore, COM701 demonstrated initial signals of anti-tumor activity in the heavily pretreated patient population enrolled on the study.
HOLON, ISRAEL, Nov. 4, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the U.S. Food and Drug Administration has cleared its investigational new drug (IND) application for COM902, its immuno-oncology therapeutic antibody targeting TIGIT in patients with advanced malignancies. Under this IND, the Company intends to initiate a Phase 1 clinical trial in patients with advanced malignancies for whom standard of care therapies are currently ineffective. Expected to begin in early 2020, the clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of COM902.
HOLON, Isreal, Oct. 28, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will ...
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
HOLON, Israel, Oct. 2, 2019 /PRNewswire/ -- October 2, 2019 – Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced it will present three posters at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019) to be held November 6-10 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland.
In a poster titled "COM701 (A Novel Immune Checkpoint Inhibitor) in Patients with Advanced Solid Tumors," the Company reported that it has completed enrollment in the seventh dose level in the COM701 monotherapy (Arm A) and second dose level in the combination of COM701 with Opdivo® (Nivolumab) (Arm B) and that no dose-limiting toxicities were observed in these and prior dose level cohorts. COM701 as a monotherapy and in combination with Opdivo has shown an acceptable safety and tolerability profile at all dose levels tested.
Anat Cohen-Dayag became the CEO of Compugen Ltd. (NASDAQ:CGEN) in 2010. This report will, first, examine the CEO...
MyoKardia (MYOK) doses the first patient in phase I study on MYK-224, which is being evaluated for treating patients with hypertrophic cardiomyopathy, a common heart disease.
Vaccinex (VCNX) completes enrollment in a phase Ib/II study of its pipeline candidate pepinemab in combination with Bavencio for treating advanced non-small cell lung cancer.
Mallinckrodt (MNK) recruits the first patient in a mid-stage study on MNK-6106 for the treatment of hepatic cirrhosis and hepatic encephalopathy.